Home  »  Espicom

Espicom Market Research Reports

The Pharmaceutical Market: Greece
THE PHARMACEUTICAL MARKET: GREECE - REVIEW The immediate threat of a Greek default and eurozone exit was reduced as the outcome of the legislative elections in June had a much more benign outcome than many feared. A n exit would have - and could still be - disastrous for drugmakers operating in the market. But even Greece staying in the monetary union means the government must continue with its austerity programme. While we continue to hold to our view that Germany and the rest of the EU may reduce the focus on austerity and introduce some pro-growth strategies, these are unlikely to generate any upside for the pharmaceutical industry and structural reforms within Greece will be maintained. T he government remains committed to huge cuts in its public drug expenditure for 2012, with a
Published Date: Apr 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Bahrain
Pharmaceuticals & Healthcare Report We expect Bahrain's pharmaceutical market values to grow steadily over the coming years. Key drivers will be volume-based, as the growing population increasingly requires more sophisticated treatments for lifestyle diseases and as healthcare provision expands and modernises . However, w hile some investment has been made into the local pharmaceutical manufacturing industry, imports will continue to supply the bulk of the demand. Headline Expenditure Projections Pharmaceuticals: BHD90mn (US$240mn) in 2011 to BHD100mn (US$260mn) in 2012; +6.12% in both local currency and US dollar terms. Forecastunchanged from Q412. Healthcare: BHD420mn (US$1.1bn) in 2011 to BHD500mn (US$1.2bn); +7.3% in both local currency and US dollar terms. Forecastu
Published Date: Apr 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Cambodia
Cambodia Pharmaceuticals & Healthcare Report Lacklustre efforts by the government to boost healthcare means that the Cambodia will be the least attractive to pharmaceutical investors as compared to its South East Asian peers as the population are unable to afford new treatments. Over the longer term we expect such trends to change and active participation in the Association of Southeast Asia Nations (ASEAN) Economic Community will boost its attractiveness. Headline Expenditure Projections Pharmaceuticals: KHR718bn (US$178mn) in 2011 to KHR806bn (US$193mn) in 2012; +12.2% in local currency terms and +8.8% in US dollar terms. Growthforecast unchanged from Q312, although we have adjusted the absolute value following reassessment of the market size. Healthcare: KHR2,982bn (US
Published Date: Apr 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Sri Lanka
Sri Lanka Pharmaceuticals & Healthcare Report Sri Lanka's negative pharmaceutical trade balance is expected to widen over the next five years. In an attempt to reduce medical costs, the government said in its 2011 budget that pharmaceutical products will be exempt from the port and airport levy, with the changes relating to drugs, medical devices and equipment. Although domestic manufacturing will struggle to compete with cheap medicines from India, we expect local producers to increase capacity considerably over the medium term. Headline Expenditure Projections Pharmaceuticals: LKR50.68bn (US$458mn) in 2011 to LKR59.90bn (US$501mn) in 2012; +18.2% in local currency terms and +9.4% in US dollar terms. Healthcare: LRK250.62bn (US$2.27bn) in 2011 to LKR278.82bn (US$2.34bn)
Published Date: Apr 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Czech Republic
OVERVIEW OF THE PHARMACEUTICAL MARKET IN CZECH REPUBLIC The recent measures proposed by the Czech Republic's Ministry of Health will, in all likelihood, negatively affect the Czech pharmaceutical market. The introduction of reimbursement ceilings, blind bidding auctions and preferential prescribing will squeeze drugmakers' margins and shift some of the burden of healthcare spending onto the private sector. The outcome of similar measures in Hungary and Poland strongly supports our view that the business environment for drugmakers will worsen if these proposals are adopted. It is patients who, ultimately, will suffer. Headline Expenditure Projections Pharmaceuticals: CZK80.71bn (US$4.56bn) in 2011 to CZK79.76bn (US$4.2bn) in 2012; -1.2% in local currency terms and -7.1% in US d
Published Date: Apr 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Denmark
OVERVIEW OF THE PHARMACEUTICAL MARKET IN DENMARK The macroenvironment for the Danish pharmaceutical industry is improving. The centre-left coalition, of the Social Democratic Party, the Socialist People's Party and the Social Liberal Party, took office in October 2011. Denmark suffered a deep recession and economic recovery is stalling with negative GDP growth projected for 2012. Denmark has an ageing population, and the Economist Intelligence Unit projects that the population aged 65 and over will constitute more than one-fifth of the total population by 2016. As a result, healthcare is increasingly focused on preventative care and there will be a continuing demand for new therapies so that patients can be treated more effectively. The increasing pharmaceutical expenditure in Den
Published Date: Apr 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Venezuela
OVERVIEW OF THE PHARMACEUTICAL MARKET IN VENEZUELA We expect the Venezuelan government to continue its foreign currency and import control policies in Q412 and the local market will endure further government restrictions on pharmaceutical and healthcare industry. Multinationals will have the potential revenue-generation opportunities from Venezuela's increasing reliance on imported products to meet local demand, as the election outcome will not fix the production capacity issues in the domestic industry. Headline Expenditure Projections Pharmaceuticals: VEB33.26bn (US$5.46bn) in 2011 to VEB40.77bn (US$6.00bn) in 2012; +22.6% in local currency terms and +10.0% in US dollar terms. Forecasts down due to new industrial information. Healthcare: VEB66.69bn (US$10.94bn) in 2011 to
Published Date: Apr 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Iraq
OVERVIEW OF THE PHARMACEUTICAL MARKET IN IRAQ Years of underinvestment have taken their toll on the Iraqi healthcare market, as have international sanctions and deterioration of healthcare infrastructure due to war. Still an unpopular figure on the international market, Iraq's trade partners are few and far between - although Iraq does have a strong bargaining chip: its oil resources. Healthcare facilities are gradually improving, with plans for new hospitals such as two specialist hospitals planned in partnership with Iran'sRed Crescent organisation. But access to funding is limited, import and exports are restricted, and the country has a severe shortage of trained medical professionals. As such, it is of little surprise that there are few distinctions in the market between OTC an
Published Date: Apr 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Lithuania
THE PHARMACEUTICAL MARKET: LITHUANIA- REVIEW We continue to hold our subdued outlook for the Lithuanian pharmaceuticals market during the next few years, on account of the changing economic and demographic situation. We expect limited low single digit growth in 2012 , with the market expected to increase by a local currency margin of 2.5% year-on-year (y-o-y) to reach LTL1.6 8 bn (US$6 18 mn) in 2012 at consumer prices. However, in US dollar terms, the market ' s value will shrink by 6.3%, in dicating the challenges facing companies operating in the market . Headline Expenditure Projections Pharmaceuticals: LTL1.64bn (US$659mn) in 2011 to LTL1.68bn (US$618mn) in 2012; +2.5% in local currency terms and -6.3% in US dollar terms. Forecastslightly upfrom Q4 12on account of new
Published Date: Apr 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Saudi Arabia
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SAUDI ARABIA Saudi Arabia' s transition to an increasingly privatised and comprehensive healthcare system will drive the demand for both patented and generic drugs . The country is investing heavily in healthcare infrastructure and we expect this will be borne out in double-digit growth forecasts across our three headline indicators. Headline Expenditure Projections Pharmaceuticals: SAR16.70bn (US$4.46bn) in 2011 to SAR18.95bn (US$5.06bn) in 2012; +13.5% in local currency and US dollar terms. Forecastbroadly unchanged from Q3 12. Healthcare: SAR78.63bn (US$21.00bn) in 2011 to SAR91.20bn (US$24.35bn) in 2012; +16.0% in local currency and US dollar terms. Forecast broadly unchanged from Q3 12. Medicaldevices: SAR5.54bn (US$1.48bn) in
Published Date: Apr 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Morocco
OVERVIEW OF THE PHARMACEUTICAL MARKET IN MOROCCO Morocco's subsidised health insurance scheme,Régime d'Assistance Médicale (RAMED),launched in March 2012,is experiencing early-stage difficulties with its target to increasehealthcare accessibilityto those on low incomes. This is to be expected, given the evidence of bribery and corruption, and the shortage of doctors in the sector.BMIbelievesthe commitment to improvegovernance and implement controls in the sector will be fulfilled in the medium-to-longterm. As such, we maintainthat government healthcare spending will outpace private healthcare spending over the forecast 2011-2016 period. Headline Expenditure Projections Pharmaceuticals: MAD10.10bn (US$1.25bn) in 2011 to MAD11.24bn (US$1.30bn) in 2012; +11.3% i
Published Date: Apr 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Serbia
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SERBIA While the market is small in terms of absolute numbers, relative per capita spending on medicines is expected to improve over the long term. As the country continues its economic convergence with developed Europe, drug consumption is also expected to rise. However, financial inefficiencies within the health insurance system mean that the National Health Insurance Institution ( RZZO ) is unable to always meet its obligations on time, leaving patients to pay for formerly reimbursed medicines or hospitals having to cover the difference . Headline Expenditure Projections Pharmaceuticals: RSD75.70bn (US$1.03bn) in 2011 to RSD81.44bn (US$0.92bn) in 2012; +7.6% in local currency terms and -11.0% in US dollar terms. Healthcare: RSD347.7
Published Date: Apr 2014
Published By: Espicom

Price: $1295
Understanding Myanmars Regional Healthcare Markets
Commercial opportunities in Myanmar's healthcare sector are mainly derived from its large unmet medical needs and underinvestment. However, we maintain that significant improvements are required if Myanmar is to realise its ambitious public health insurance scheme. In addition, political uncertainties from the upcoming election in 2015 may also deter investors over the short term. Decades of military control have meant that the majority of Myanmar's expenditure has gone into military/defence, with less spent on other sectors including health provision. As a result of low government health expenditure, healthcare access in the country is severely lacking. The country's decision to open up its economy in 2012 has attracted strong foreign interest, and saw the entry of a number of compa
Published Date: Mar 2014
Published By: Espicom

Price: $935
Understanding South Africas Regional Healthcare Markets
With a new National Health Insurance system being implemented, what will the effects be on the under-resourced public sector and the expensive private sector? And what changes can be seen at the varied regional and provincial levels? Any assessment of South Africa must consider the potential variations across Eastern Cape, Free State, Gauteng, KwaZulu-Natal, Limpopo, Mpumalanga, North West, Northern Cape and Western Cape, as well as down to provincial levels. Geographical diversity will impact on medical services and this report answers those key questions that will arise: How is the population distributed? How is healthcare divided? Health funding: How is the Government expenditure vs. private expenditure indicated? What are the long-term macroeconomic forecasts? Which region
Published Date: Mar 2014
Published By: Espicom

Price: $935
Medical Device Pricing & Reimbursement 2014
Provides insight into medical device pricing and reimbursement systems and latest regulations across 17 key countries! This guide provides everything you could need to know about medical device pricing and reimbursement in 17 established and emerging economies. It examines the increasing role that health technology assessment plays in the reimbursement decision-making process and procurement strategies - both of which have a direct impact on device pricing. Countries covered in this report: Asia/Pacific: Australia, China, Japan and South Korea European Union: Belgium, France, Germany, Italy, The Netherlands, Spain and United Kingdom Latin America: Brazil, Chile, Colombia, Mexico and Peru USAHealth Technology Assessment (HTA) plays a key role in the increasing trend of val
Published Date: Mar 2014
Published By: Espicom

Price: $995
The Pharmaceutical Market: Moldova
Moldova Pharmaceuticals & Healthcare Report Given the high level of reliance on out-of-pocket payments, the growth of the Moldova's pharmaceutical market is expected to be shaped by the prevailing economic conditions, both at home and abroad, on account of the importance of remittances to the country's GDP. For 2012, we expect the market's value to increase at a local currency rate of 6.7%, although this will translate into negative US dollar growth, on the back of a weak leu . Headline Expenditure Projections Pharmaceuticals: MDL2.47bn (US$211mn) in 2011 to MDL2.64bn (US$204mn) in 2012; +6.7% in local currency terms and -3.0% in US dollar terms. Forecastunchanged from Q4 12. Healthcare: MDL9.06bn (US$773mn) in 2011 to MDL9.64bn (US$747mn) in 2012; +6.4% in local currenc
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Russia
OVERVIEW OF THE PHARMACEUTICAL MARKET IN RUSSIA The Russian pharmaceutical market remains a powerhouse in the Emerging Europe region . The country has by far the larg est population in the region. I ts resource s -driven economic growth is funding both private and public spending on medicines and healthcare services. The country's World Trade Organisation (WTO) accession has eliminated tariff barriers and should, in the long run, drive major improvements in a problematic intellectual property environment. Both domestic and cross-border mergers and acquisitions (M&A) activity has picked up since the 2009 economic crisis, a result of increased incentives for local production under the government's industrial policy for the sector and the need for scale to compete , especially i
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Spain
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SPAIN The sharp drop in public pharmaceutical expenditure in Spain in the first four months of 2012 serves as a warning for the continuation of a fall in spending on medicines in the remainder of the year. BMI notes that this does not bode well for drugmakers selling their products in Spain as the success of the implemented policies may encourage the enforcement of further cost-containment measures, which, together with the ongoing public hospital debt situation, seriously hampers the country's attractiveness as a location in which to sell drugs, despite its favourable demographic characteristics. Headline Expenditure Projections Pharmaceuticals: EUR20.15bn (US$28.00bn) in 2011 to EUR18.34bn (US$23.30bn) in 2012; -9.0% in local curre
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: United Kingdom
OVERVIEW OF THE PHARMACEUTICAL MARKET IN UNITED KINGDOM Drugmakers and governments will increasingly enter agreements that provide some form of risk- sharing or price protection for new drugs. Since most European governments, including the UK authorities, are focussing on cost containment in the healthcare sector, alternative pricing schemes for medicines allow for budget control, as well as providing patients with access to highly innovative treatments. Guidance drafted by the National Institute for Health and Clinical Excellence (NICE) has recommended the use of Bristol-Myers Squibb 's Yervoy (ipilimumab) and Roche's Zelboraf ( vemurafenib) for the treatment of advanced skin cancer. These are the first new drugs approved for routine use by the UK's National Health Service for the
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: India
OVERVIEW OF THE PHARMACEUTICAL MARKET IN INDIA The outlook for India's patented drug market is not promising. The primary reason why sales of these products will not grow swiftly is the country's intellectual property (IP) regime, which is well below international standards. It does not recognise incremental improvements and as such few medicines receive exclusivity. The outlook is also restricted by the government's apparent desire to spend as little as possible on medical services. Whileprudenceis virtuous in an indebted global economy, India still needs to spend the 'market rate' for healthcare infrastructure, doctors, nurses, medical devices and innovative pharmaceuticals. Without the necessary therapeutics, healthcare rofessionals, hospitals andclinics, India's healthcare i
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Finland
OVERVIEW OF THE PHARMACEUTICAL MARKET IN FINLAND The macroenvironment for the Finnish pharmaceutical industry is improving.Politically, the new six-party coalition is larger and represents a broader spectrum of opinion than is usual, which could make it unstable. However, the Economist Intelligence Unit (EIU) believes that it will last out its four-year term. Economically, recovery from the downturn is stalling due to the euro area debt crisis. Legally, Finland remains on the USTR’s Watch List in 2011 due to concerns over patent protection. Demographically, Finland has one of the largest proportions of population over the age of 65 in Western Europe. Latest projections expect that the population aged 65 and over will constitute more than one-fifth of the total population by 2017
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Belarus
Pharmaceuticals & Healthcare Report We remain largely pessimistic about the Belarus' pharmaceutical market development in the short term at least. While the government remains committed to boosting domestic pharmaceutical output over the coming years, with authorities in manufacturing joint venture (JV) discussions with a number of countries, the devalued rouble, high inflation and weak household consumption will continue to constrain both volume and value of medicines consumed in the country. We also note increased political and also economic risks, as the country aligns itself away from the European Union (EU). Headline Expenditure Projections: Pharmaceuticals: BYR3,598bn in 2011 (US$692mn) to BYR5,623bn (US$686mn) in 2012; +56.3% in local currency terms and -1.0% in
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Israel
THE PHARMACEUTICAL MARKET: ISRAEL- REVIEW Although Israel claims its very efficient healthcare system means it does not need to spend as much of its GDP on provision (some 7.6% was spent on this purpose in 2011), in reality the government's fiscal austerity and sick funds traditionally keep the most expensive innovative drugs and treatments unavailable. Additionally, as healthcare providers are prohibited from taking on debt, the shortage means that cheaper generics and low staff salaries have to be used to control overall costs, which often comes at the expense of services provided to patients. However, the recent ruling means that the state must increase payments to healthcare providers in order to account for rising costs, which provide some upside risks to healthcare forecasts.&n
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Switzerland
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SWITZERLAND While the patent cliff and the consequent availability of generic drugs, as well as price cuts on generic medicines and their increasing affordability, will work towards increasing the consumption of generic medicines in Switzerland, BMI believes the government needs to do more to alter patients' attitudes towards these drugs as this the main deterrent of growth. Headline Expenditure Projections Pharmaceuticals: CHF6.77bn (US$7.63bn) in 2011 to CHF6.58bn (US$7.00bn) in 2012; -2.8% decline in local currency terms and -8.2% in US dollar terms. Healthcare: CHF65.30bn (US$73.6bn) in 2011 to CHF67.42bn (US$71.72bn) in 2012; +3.2% growth in local currency terms and -2.6% in US dollar terms. Medical devices: CHF4.77bn (US$5.38
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Brazil
OVERVIEW OF THE PHARMACEUTICAL MARKET IN BRAZIL The Brazilian pharmaceutical market remains our favourite regional market in Latin America due to its large market size and strong domestic demand for innovative, high-tech products. The government i s increasing ly invest ing in the healthcare sector and pharmaceutical industry to reduce the financial burden of diseases , and the country's private healthcare sectors provide opportunities for foreign companies. However, the increasing d rug rebate level has significantly undermined the profits recorded by generic drugmakers. The more aggressive government techonology transfer deals with multinationals as well as the drug approval delays due to bureaucracy and staff shortages at ANVISA have also dampened multinationals' revenue-generati
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Kuwait
Kuwait Pharmaceuticals & Healthcare Report Kuwait's small population, and the fact that many residents are expatriates means that the country's healthcare market is closely linked to that of neighbouring Arab nations. Private healthcare accounts for around a fifth of total spending, and the government funds treatment for many nationals abroad. As Kuwait's population expands, grows older, and the incidence of non-communicable diseases such as diabetes and obesity increases, the government is coming under increasing pressure to improve its domestic facilities. In 2010 it embarked on a US$108bn project to add 3,500 beds to hospitals and boost healthcare facilities; once completed, the government estimates it will need an additional 15,000 healthcare professionals in the country.
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Malaysia
OVERVIEW OF THE PHARMACEUTICAL MARKET IN MALAYSIA Malaysia ' s healthcare sector is showing strong signs of growth, with increased internal and investment in pharmaceutical manufacturing facilities in a move to boost exports. Key growth areas include biotechnology; namely drug discovery, new product development , technology acquisition and licensing ; generic drug production; and the recent release of h alal pharmaceutical guidelines mean s Malaysia has the potential to take a le ading role in the fast-growing h alal pharmaceutical market. While concerns remain regarding intellectual property - Malaysia has presented objections to elements in the Trans-Pacific Partnership Agreement - it is making progress in terms of trade relations: the government began negotiations over the creatio
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Portugal
OVERVIEW OF THE PHARMACEUTICAL MARKET IN PORTUGAL Portugal 's pharmaceutical and healthcare sector has been transformed since the intervention of the EU, IMF and ECB as part of the country's EUR78bn economic rescue package approved in May 2011 . The latest review states that Portugal has already made considerable savings in the healthcare sectors, with changes such as the introduction of e-prescriptions and prescribing by active ingredients, changes to reference pricing, reductions in pharmacy margins and price cuts just some of the measures in place. The impact on the market has been widespread. Spending has been slashed and both domestic and multinational pharmaceutical firms have seen their profits shr i nk. Data recently published by Infarmed show that Portugal has dropped from
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Egypt
OVERVIEW OF THE PHARMACEUTICAL MARKET IN EGYPT As anticipated by BMI, Egyptian President Mohammad Morsi's relative success in his first100days in officehighlights a degree of political and economic stability,which we believehas resulted in a final resolution of the medicines pricing system. We highlight that our expectation of the government imposing pharmaceutical price caps and adopting a controlled, low-pricing strategy has played out. The new pricing systemsets theprices of medicines higher than the old cost-plus system and BMImaintains this will be good for multinational companies in the mediumterm. However, the dangers of a possible downward pricing spiral, due to the interdependence of countries in the reference pricing basket, is along-term risk to multinationals'revenues.
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Iran
OVERVIEW OF THE PHARMACEUTICAL MARKET IN IRAN We caution that our forecasts for the Iranian pharmaceutical market are at considerable risk due to runaway inflation and political risks. We also point out that the official exchange rate does not follow the trends in the black market, which further distorts market valuations. While our local currency forecast for the market's development is broadly in line with the previous quarter's figure, the value in US dollar terms will be considerably impacted by rising inflation, caused by the sanction induced currency crisis. At the same time, we expect that the volume of pharmaceutical sales in the country will continue to be negatively impacted by the prevailing economic and political conditions. These have already resulted in shortages of c
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Peru
OVERVIEW OF THE PHARMACEUTICAL MARKET IN PERU We have recently revised downwards our 2012 pharmaceutical sales growth for Peru, due to the recent price cuts in the prescription drug sector, which accounts for over 74% of total pharmaceutical sales. Still, our projected compound annual growth rate (CAGR) between 2011 and 2016 remains largely unchanged as BMI believes Peru still offers considerable longer-term benefits to local and foreign pharmaceutical companies because of the country's ageing population, increasing disease burden and the expected change in drug consumption patterns. Headline Expenditure Projections Pharmaceuticals: PEN3.90bn (US$1.42bn) in 2011 to PEN4.11bn (US$1.57bn) in 2012; +5.3% in local currency terms and +10.4% in US dollar terms. Forecast revised d
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: France
OVERVIEW OF THE PHARMACEUTICAL MARKET IN FRANCE France\'s high public debt-to-GDP ratio will necessitate more aggressive fiscal tightening by the state. This includestargeting the pharmaceuticals and healthcare sector, whichcurrentlyreceivesa large proportion of public funds. Headline Expenditure Projections Pharmaceuticals: EUR35.01bn (US$48.66bn) in 2011 to EUR34.17bn (US$43.39bn) in 2012. -2.4% in local currency terms and -10.8% in US dollar terms. Local currency forecast broadly unchanged from Q3 12. Healthcare: EUR234.30bn (US$325.68bn) in 2011 to EUR239.29bn (US$303.89bn) in 2012; +2.1% in local currency terms and -6.7% in US dollar terms. Local currency forecastslightly lower from Q312on account of worsening macroeconomic environment. Medical devices: EUR10.72bn
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Belgium
OVERVIEW OF THE PHARMACEUTICAL MARKET IN BELGIUM We remain less than optimistic about the short- term growth of the Belgian pharmaceutical market. Through to 2016, the market's value is expected to post a negative compound annual growth rate (CAGR) of -1% in both local currency and US dollar terms, largely on account of cost containment measures and patent expirations. Nevertheless, foreign companies are expected to continue using Belgian pr oduction sites for exports, the country also being a popular re-export source. Headline Expenditure Projections Pharmaceuticals: EUR6.12bn (US$8.51bn) in 2011 to EUR5.96bn (US$7.57bn) in 2012; -2.6% in local currency terms and -11.0% in US dollar terms. Local currency forecast broadly unchanged from Q412. Healthcare: EUR38.96bn (US$54.
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Philippines
THE PHARMACEUTICAL MARKET: PHILIPPINES - REVIEW The Philippine economy expanded by an impressive 5.9% year-on-year in Q2 12 due to strong growth from various sectors, such as services and exports. Consequently, we have upgraded the pharmaceutical market forecast. We continue to hold our view that pharmaceutical firms will see short-term opportunities in the Philippines due to ineffective governance of the prices of drugs. Headline Expenditure Projections Pharmaceuticals: PHP126.04bn (US$2.91bn) in total sales in 2011, rising to PHP129.96bn (US$2.89bn) in 2012; +3.1% in local currency terms and +3.3% in US dollar terms. Forecastup slightlyfrom Q412due to improved macroeconomic outlook. Healthcare: PHP364.95bn (US$8.43bn) in sales in 2011 rising to PHP408.26bn (US$9.45bn) in
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Uganda
OVERVIEW OF THE PHARMACEUTICAL MARKET IN UGANDA While geographic diversification and investment into the pharmaceutical and healthcare sector of emerging economies such as Uganda may be a favourable strategy for any multinational pharmaceutical company - it is vital that a company recognises both the rewards and the risks present in a market. With regards to assessing risks in the Ugandan healthcare sector, we have identified industry specific dangers (such as low per-capita spending and poor access to healthcare facilities) and those emanating from the state's political/economic profile (such as high inflation) that call into question the likelihood of anticipated returns being realised over the assessed time period. Headline Expenditure Projections Pharmaceuticals: UGX676bn (
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Ukraine
OVERVIEW OF THE PHARMACEUTICAL MARKET IN UKRAINE Foreign and domestic drugmakers in Ukraine will see their operating margins squeezed from2013as the Ministry of Health introduces more severe limitson mark-ups. Combined with the likely devaluation of the hryvnia, these factors represent a very large business risk for international drugmakers operating in the country. While Ukraine remains one of Central and Eastern Europe (CEE)'s more promising pharmaceutical markets given its favourable demographics and disease profile, its chronic lack of economic and political stability remains a critical impediment to fulfilling this potential. Headline Expenditure Projections Pharmaceuticals: UAH26.75bn (US$3.35bn) in 2011 to UAH30.79bn (US$3.75bn) in 2012; +15.1% in local currency term
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Zimbabwe
Zimbabwe Pharmaceuticals & Healthcare Report Regardless of the outcome of the upcoming general elections, scheduled for November 2012, we remain pessimistic about the short - to medium - term development of Zimbabwe's pharmaceutical market. While the need for medicines is vast, the majority of demand continues to be met through foreign donations, indicating the dire situation in the country. At the same time, the domestic industry continues to struggle, without much hope for government finances or credit extensions, which will continue to exacerbate the already massive problems with regard to access to medicines. Headline Expenditure Projections Pharmaceuticals: US$160mn in 2011 to US$180mn in 2012; +12.7% in US dollar terms. Forecast in line with Q3 12. Healthcare US$
Published Date: Mar 2014
Published By: Espicom

Price: $1295
The Pharmaceutical Market: Singapore
OVERVIEW OF THE PHARMACEUTICAL MARKET IN SINGAPORE Singapore will be of moderate attractiveness to investors given its small pharmaceutical market size, despite the growing demands for more pharmaceuticals and healthcare from its increasingly ageing population. However, the city-state will continue to attract companies looking to set up regional offices, manufacturing hubs or research and development facilities in the country given its strong regulatory framework and relatively stable political and economic environment. Headline Expenditure Projections Pharmaceuticals: SGD901mn (US$716mn) in 2011 to SGD942mn (US$751mn) in 2012; +4.5% in local currency terms and +4.9% in US dollar terms. Forecast broadly in line with previous quarter. Healthcare: SGD13.1bn (US$10.4bn) in 201
Published Date: Mar 2014
Published By: Espicom

Price: $1295
Understanding Vietnams Regional Health Markets
With the implementation of a universal healthcare system on the horizon, Vietnam’s health infrastructure is looking up – but what affect will this have on the current infrastructure? And what changes can be seen at the varied regional and provincial levels? A forensic analysis with statistics on national and regional health infrastructure and provision. An essential source of highly detailed business data With the implementation of a universal healthcare system on the horizon, Vietnam’s health infrastructure is looking up – but what affect will this have on the current infrastructure? And what changes can be seen at the varied regional and provincial levels? Any assessment of Vietnam must consider the potential variations across Central Highlands, Mekong De
Published Date: Feb 2014
Published By: Espicom

Price: $935
Advances in the Rheumatoid Arthritis Market
Rheumatoid arthritis (RA) is a chronic disorder for which there is currently no cure. It affects around 23.5 million adults in the world (WHO, 2013) and approximately 294,000 children under the age of 18 are affected by pediatric arthritis and other rheumatologic conditions (PhRMA, 2013). In 2012, immunology drugs generated global sales of around US$36.6bn of which two thirds were associated with the management rheumatology related conditions (US$24.5bn), the remainder of sales were split evenly between the treatment of dermatological and gastroenterology related conditions. Revenues growth has been driven by improvements in diagnosis and early, more aggressive treatment of RA, the approval of new disease modifying anti rheumatic drugs (DMARDs), new formulations/devices and line extensi
Published Date: Jan 2014
Published By: Espicom

Price: $1295
Generic Drugs: Global collaboration opportunities
Collaboration is the key to growth With the recent economic turmoil affecting many markets around the world, the generic and branded sectors face similar problems. At one time the generic sector was seen as a valuable way to bring effective products to a wider audience. This, allied to the rising cost of new advanced branded products, led to rapid expansion of the generics sector. Even markets traditionally based in the provision of branded medicines have made moves to increase generic prescribing. But pressure on health spending is seeing downward pressure on generic prices. With lower margins this is creating pain for generics companies. SME Generic companies offer focused opportunities With established markets compromised, where can the industry go? Expansion in t
Published Date: Jan 2014
Published By: Espicom

Price: $1250
Trends and Opportunities in the Diabetes Care Market
This report provides everything you need to know about the current market for diabetes care devices; from detailed analysis of the products, companies and developments influencing its growth to an in-depth manufacturer directory detailing company movements within the market and key financial data (where available). The global market for diabetes devices was estimated to be worth US$ 12.2 billion in 2012. And although this market was in decline due to intense competition and low reimbursement levels, as well as being traditionally dominated by 6 major manufacturers, good opportunities are growing more apparent for companies with unique diabetes devices or that compete in yet to be established markets. In geographical terms, the US market dominates this sector, with Europe and other
Published Date: Jan 2014
Published By: Espicom

Price: $1545
Advanced in the Rheumatoid Arthritis Market
Rheumatoid arthritis (RA) is a chronic disorder for which there is currently no cure. It affects around 23.5 million adults in the world (WHO, 2013) and approximately 294,000 children under the age of 18 are affected by pediatric arthritis and other rheumatologic conditions (PhRMA, 2013). In 2012, immunology drugs generated global sales of around US$36.6bn of which two thirds were associated with the management rheumatology related conditions (US$24.5bn), the remainder of sales were split evenly between the treatment of dermatological and gastroenterology related conditions. Revenues growth has been driven by improvements in diagnosis and early, more aggressive treatment of RA, the approval of new disease modifying anti rheumatic drugs (DMARDs), new formulations/devices and line ext
Published Date: Jan 2014
Published By: Espicom

Price: $1545
Telecare: Healthcare For The Next Generation
Telecare: Healthcare For The Next Generation Growth in the number of mobile phone users and wireless subscribers, and advances in the innovative application of communication technology to address health priorities have the potential to transform the delivery of healthcare across the world. This provides significant opportunities for companies looking to invest in the telecare sector. Espicom/BMI defines telecare as the use of mobile and internet technology to provide clinical care and non-clinical services, such as health education, disease surveillance and drug monitoring. It is our view that a combination of factors - including the continued growth in demand for and delivery of healthcare, the sustained growth in mobile and broadband subscribers and penetration rates and the g
Published Date: Dec 2013
Published By: Espicom

Price: $995
Understanding Turkeys Regional Health Markets
Even with Turkey’s significant population growth, this country has transformed its healthcare sector over the past decade. As its economy flourished, there was a huge increase in spending on infrastructure – but is the distribution of this healthcare equal? And what opportunities could this provide for more undeveloped areas? Any assessment of Turkey must consider the potential variations across Aegean, Central Anatolia, East Marmara, the Eastern Black Sea, Istanbul and the Mediterranean, Middle Eastern Anatolia, Northeast Anatolia Southeast Anatolia, West Marmara, Western Anatolia and the Western Black Sea, as well as down to provincial levels. Geographical diversity will impact on medical services and this report answers those key questions that will arise: How is
Published Date: Dec 2013
Published By: Espicom

Price: $935
Understanding Saudi Arabias Regional Health Markets
Understanding Saudi Arabia's Regional Health Markets Saudi Arabia is the 43rd most populated country in the world, with a population of 29mn (according to estimates for 2012). Made up of nationals, an important expatriate population and an estimated 2mn illegal immigrants, Saudi Arabia's healthcare market is split between public and a growing private sector. It is also put to the test at key times in the Islamic calendar, when Muslim pilgrims travel to key holy sites across the country. We have divided Saudi Arabia into five regions, and the key highlights from each region's healthcare market are outlined below: Central region - The central region of Saudi Arabia - which we define as being formed of the province of Riyadh (home to the capital city, of the same name), H
Published Date: Dec 2013
Published By: Espicom

Price: $935
Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013
The market for injectable generics has been through a period of consolidation over the last few years as the leading companies have increased their presence through acquisition. The major players include Hospira, Sandoz (Novartis), Hikma Pharmaceuticals, Fresenius Kabi and Teva Pharmaceutical Industries. But interest in generic injectables has not been limited to established generic companies, as pharmaceutical majors like Pfizer have also become attracted to the market. This is hardly surprising with a global injectables market in the region of US$144 billion. While the lion’s share remains with the innovative industry for the time being, the generic injectables market is worth around US$12.2 billion and numerous high value injectable products will face patent expiry in major m
Published Date: Dec 2013
Published By: Espicom

Price: $1740
Understanding Malaysias Regional Healthcare Markets
Understanding Malaysia's Regional Healthcare Markets With an estimated population of 29.4mn people in 2012, Malaysia is the 42nd most populated country in the world. It is in the midst of an Economic Transformation Programme that aims to help reach the goal of having high-income status by 2020, but the benefits of this programme are uneven – different parts of the country are growing at different rates. Similar trends can be seen in healthcare, with the quality of care, and the burden of disease, affected by factors such as climate, population density, topographical barriers and the spending power of individual states. This report combines these factors, to give a picture of healthcare trends and forecasts across the country. Highly-detailed and granular healthcare report pr
Published Date: Nov 2013
Published By: Espicom

Price: $935
Inhalation & Nasal Spray Generic Drugs 2013
Around three quarters of the US$36.4 billion respiratory prescription drugs market comprises drugs that are delivered using inhalation or nasal spray technologies. The top five drugs used in the treatment of asthma and chronic obstructive pulmonary disease (COPD) attracted combined revenues of around US$18.0 billion in 2012. All five are blockbuster drugs. The current market leader overall is GlaxoSmithKline’s Seretide/Advair (fluticasone propionate+salmeterol xianfoate), with sales of US$8.0 billion. Boehringer Ingelheim’s leading COPD therapy, Spiriva (tiotropium bromide) achieved sales of US$4.6 billion. In third place was AstraZeneca’s Symbicort (budesonide+formoterol), with sales of US$3.2 billion. In the allergy segment, the leading nasal spray therapy used in the
Published Date: Nov 2013
Published By: Espicom

Price: $1740
Understanding the UAEs Regional Healthcare Markets
Understanding the UAE's Regional Healthcare Markets A federation of seven emirates, the UAE is one of the economic power houses in the Gulf region, and its strengths in industries such as oil, real estate, construction, financial services and tourism are a magnet for migrant workers. With a population of 9.1mn, the UAE's population is dynamic - much of the country has experienced rapid growth in recent years, and in some parts of the country, the healthcare sector has not managed to keep up with the rate of change. In this report, we address the challenges faced by the healthcare sector in each emirate, and how economic, demographic and other factors shape the provision of healthcare across the country. Highly-detailed and granular healthcare report providing a unique evaluation
Published Date: Nov 2013
Published By: Espicom

Price: $935
Middle East North Africa Pharmaceutical Market Forecasts to 2018
The global pharmaceutical market is forecast to be worth over US$1,250 billion by 2018 - but where are the key opportunities? And how does Middle East North Africa fit into this global outlook? This analysis report, Middle East North Africa Pharmaceutical Market Forecasts to 2018 (published November 2013), is an essential resource for business forecasters, marketing planners, the investment community and anyone looking to understand the future outlook for the challenging pharmaceutical industry within this region. You will benefit from: Growth forecasts to 2018 for 13 key country markets Comparative data on a regional basis Rankings by indicators allowing ‘at a glance’ benchmarking of countries Detailed information on each market PDF delivery with Excel data pa
Published Date: Nov 2013
Published By: Espicom

Price: $1495
Americas Pharmaceutical Market Forecasts to 2018
The global pharmaceutical market is forecast to be worth over US$1,250 billion by 2018 - but where are the key opportunities? And how does the Americas fit into this global outlook? This analysis report, The Americas Pharmaceutical Market Forecasts to 2018 (published November 2013), is an essential resource for business forecasters, marketing planners, the investment community and anyone looking to understand the future outlook for the challenging pharmaceutical industry within this region. You will benefit from: Growth forecasts to 2018 for 11 key country markets Comparative data on a regional basis Rankings by indicators allowing ‘at a glance’ benchmarking of countries Detailed information on each market PDF delivery with Excel data pack Easily exported data
Published Date: Nov 2013
Published By: Espicom

Price: $1495
Asia Pharmaceutical Market Forecasts to 2018
The global pharmaceutical market is forecast to be worth over US$1,250 billion by 2018 - but where are the key opportunities? And how does Asia fit into this global outlook? This analysis report, Asia Pharmaceutical Market Forecasts to 2018 (published November 2013), is an essential resource for business forecasters, marketing planners, the investment community and anyone looking to understand the future outlook for the challenging pharmaceutical industry within this region. You will benefit from: Growth forecasts to 2018 for 18 key country markets Comparative data on a regional basis Rankings by indicators allowing ‘at a glance’ benchmarking of countries Detailed information on each market PDF delivery with Excel data pack Easily exported data to enhance your
Published Date: Nov 2013
Published By: Espicom

Price: $1495
Central and Eastern Europe Pharmaceutical Market Forecasts to 2018
The global pharmaceutical market is forecast to be worth over US$1,250 billion by 2018 - but where are the key opportunities? And how does Central and Eastern Europe fit into this global outlook? This analysis report, Central and Eastern Europe Pharmaceutical Market Forecasts to 2018 (published November 2013), is an essential resource for business forecasters, marketing planners, the investment community and anyone looking to understand the future outlook for the challenging pharmaceutical industry within this region. You will benefit from: Growth forecasts to 2018 for 11 key country markets Comparative data on a regional basis Rankings by indicators allowing ‘at a glance’ benchmarking of countries Detailed information on each market PDF delivery with Excel dat
Published Date: Nov 2013
Published By: Espicom

Price: $1495
The Medical Device Market: Malaysia
OVERVIEW OF THE MEDICAL MARKET IN MALAYSIA Malaysia’s medical devices and supplies are mainly imported, especially the more technologically advanced items. Espicom estimates current growth in the market to be a strong 15.9% per year, reaching US$2.8 billion, or US$90 per capita, by 2017. The major natural resource is rubber, and the country’s medical device exports are dominated by latex products such as surgical gloves. The share of this sub-category has slowly started to diminish with the steady growth of diagnostic imaging exports in recent years, particularly electrocardiographs and other electrodiagnostic apparatus. The Malaysian government has attempted in recent years to encourage domestic manufacturers to expand production into more technologically advanced p
Published Date: Oct 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Netherlands
OVERVIEW OF THE MEDICAL MARKET IN THE NETHERLANDS The Netherlands has an advanced and open economy at the heart of the EU. GDP is the fifth largest in the eurozone, standing at US$838.9bn in 2013, equal to US$50,193 per capita. This makes the Netherlands one of the wealthier countries in the EU in per capita terms. The Netherlands has a long history of providing accessible healthcare, although resources are comparatively low for a Western European country. A mandatory health insurance scheme was introduced in January 2006. This replaced the previous two-tier system and provides basic health insurance cover for acute care services with a separate scheme for long term medical care. The new health insurance act has substantially increased price competition amongst insurers and healt
Published Date: Oct 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Vietnam
OVERVIEW OF THE MEDICAL MARKET IN THE VIETNAM Public hospitals struggle to fund upgrades to facilities; a change of regulations in 2012 means that public hospitals can now access funding directly from credit institutions, including the Vietnam Development Bank. As of January 2013, 18 hospitals had applied for funding with six hospitals signing contracts for loans totalling VND900bn (US$43.2mn). The private healthcare sector in Vietnam has expanded since the lifting of the ban on private practice in 1989. People often choose to use private facilities, if they can afford to do so, as the quality of state healthcare provision is very poor. According to latest data for 2012, an estimated 61.3% of healthcare expenditure was private. Approximately 40,000 Vietnamese people travel abroad f
Published Date: Oct 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Belgium
OVERVIEW OF THE MEDICAL MARKET IN BELGIUM The Belgian market for medical equipment and supplies is valued at US$2.2 billion in 2012, equal to US$207 per capita.  With GDP per capita in the region of US$43,600 in 2013, Belgium is one of the wealthier EU countries and has one of the most open economies in the world. There are, however, marked differences between the three largely autonomous regions of Brussels, Flanders and Wallonia, which between them have a combined population of around 11 million. Belgium’s six-party coalition government under the premiership of Elio Di Rupo has entered its second year. Major differences over the devolution of power to the regional governments and taxation issues hampered the formation of a new government after the general election i
Published Date: Oct 2013
Published By: Espicom

Price: $1295
Recent Developments in the CNS Drug Market
This report reviews the global market for CNS prescription drugs and recent developments within the marketplace, including collaborative agreements, recent clinical trial results and new product approvals across 8 key therapy areas. Despite recent technological advances, relatively few novel treatments have been launched within the CNS market over the last decade. Many of the current market leaders are beginning to face generic competition or will do within the next five years. However, the overall neuroscience market is worth approximately US$145.3 billion, and with the CNS market forming a large part of that, there is room for investment to be made. Significant unmet need remains for a number of CNS conditions and the pipeline of drug development remains strong. This new repor
Published Date: Oct 2013
Published By: Espicom

Price: $995
The Medical Device Market: Bulgaria
OVERVIEW OF THE MEDICAL MARKET IN BULGARIA Bulgaria is located in south-eastern Europe, bordering Romania, Serbia, Macedonia, Greece and Turkey and is one of the newest members of the EU, joining in January 2007, alongside Romania. The population of Bulgaria is estimated at 7.3 million in 2013, 18.4% of whom are aged 65 or over. The Prime Minister of Bulgaria is Boyko Borissov, leader of the GERB and former major of Sofia. The current president is Rosen Plevneliev, who took office in January 2012. In per capita terms, Bulgaria is one of the poorest countries in Central & Eastern Europe. The current figure of US$7,502 is around half that found in Russia and is similar to Serbia. GDP is low, estimated at US$55.1 billion in 2013. Real growth of 0.5% is expected in 2013. GDP will i
Published Date: Sep 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Chile
OVERVIEW OF THE MEDICAL MARKET IN CHILE Chile is situated on the Pacific Coast of South America and borders Peru, Bolivia and Argentina. It covers an area of 756,626 Km².Administratively, the country is divided into 15 regions; Aisen del General Carlos Ibanez del Campo, Antofagasta, Araucania, Arica y Parinacota, Atacama, Biobio, Coquimbo, Libertador General Bernardo O'Higgins, Los Lagos, Los Rios, Magallanes y de la Antartica Chilena, Maule, Region Metropolitana (Santiago de Chile), Tarapaca and Valparaiso. The capital is Santiago de Chile. The President, elected by popular vote for a single four-year term, is both the head of state and head of the government. With the return of former President Michelle Bachelet as its standard bearer, BMI believes that the Concertació
Published Date: Sep 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Croatia
OVERVIEW OF THE MEDICAL MARKET IN CROATIA The Republic of Croatia is located in Central Europe and is bordered by Slovenia, Hungary, Serbia, Bosnia-Herzegovina and Montenegro. In 2013, the population stands at an estimated 4.4 million.  The President of Croatia is Ivo Josipovic, who was elected as in January 2010. The Prime Minister, who is accountable to the Sabor (Parliament), is Zoran Milanovic, who took office in December 2011. The government is led by the centre-left Social Democratic Party and supported by the Croatian People's Party, the Istrian Democratic Assembly and the Croatian Pensioners' Party. The government views EU membership as a priority. Croatia applied for EU membership in February 2003 and has worked hard to align its legislation with the EU acquis. Cro
Published Date: Sep 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Denmark
OVERVIEW OF THE MEDICAL MARKET IN DENMARK BMI believes that the biggest risk to Denmark's medium-term macroeconomic trajectory stems from ongoing economic and financial developments within the eurozone. Denmark has sizeable trade and investment linkage with the common currency bloc, and a major deterioration in growth in the core countries could push Denmark back into recessionary territory this year. Real GDP growth is forecast at 1.2% in 2013, with GDP reaching US$318.0bn, equal to US$56,668 per capita. Denmark joined the EU in 1973, but has so far declined to adopt the euro as its currency. According to the Ministry of Health & Prevention, the Danish regions plan to invest up to DKK41.4bn (US $7.4bn) in the construction of 16 new public hospitals. By 2012, nine of the 16 new
Published Date: Sep 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Estonia
OVERVIEW OF THE MEDICAL MARKET IN ESTONIA Funding for healthcare in Estonia is principally through a national health insurance system, which came into effect in the 1990s. Healthcare is supposed to be available free under it, but funding has never matched demand, and patient payments for services remain common. In 2013, the Estonian market for medical equipment and supplies is estimated at US$152.9 million, or US $114.2 per capita. The small size of the market limits scope for the purchase of more expensive items. The market is projected to grow at a CAGR of 4.1% over the forecast period, reaching US$186.6 million in 2018, equal to US$140.0 per capita. Nearly 80% of the medical device market is supplied by imports, principally from western suppliers. There is a small domestic pr
Published Date: Sep 2013
Published By: Espicom

Price: $1295
Advances in the Obesity Market
This report reviews the current state of the obesity market for both pharmaceuticals and medical devices, examining why the obesity market is of such importance across established and emerging economies and how current interventions measure up. In July 2011, the American Association of Clinical Endocrinologists (AACE) reclassified obesity as a diseased state, not a condition, in order to move it up the US healthcare agenda. In 2012, the FDA reviewed its stance on anti-obesity products and approved two new products that were previously declined. As it stands, there are over 40 medicines currently approved or used off label to treat obesity, in addition there are more than 20 innovative products in clinical development. This new report examines the latest products and devices in deve
Published Date: Sep 2013
Published By: Espicom

Price: $1495
Understanding Indonesias Regional Health Markets
Often overshadowed by its larger Asian neighbours such as China and Japan, Indonesia is the largest economy in the ASEAN community. With a young and fast growing population, Indonesia’s challenge is to ensure that the benefits of its rapidly growing economy are more effectively utilised in providing a good level of healthcare to its 237 million inhabitants.  Any assessment of Indonesia must consider the geographic diversity of the country and the economic and demographic dynamics that are influencing the development of the health market.  How is wealth distributed regionally? Which regions produce the highest levels of GDP and does that relate to health spending? What role is played by private healthcare? How is the population distributed? How is healthcare orga
Published Date: Sep 2013
Published By: Espicom

Price: $935
Cardiovascular Device Companies: Surveying the Global Competitive Landscape
This continuously-updated report enables customers to evaluate the competitive landscape and identify the companies to look out for in the future. It provides an insight into who’s striking strategic and tactical partnerships, along with the latest in regulatory developments and M&A activity. A complete picture... This fully revised 376-page report provides a complete a picture of how robust the cardiovascular device sector is and how well companies are performing. AN OVERVIEW OF PRODUCT APPROVALS AND REGULATORY ISSUES IN THE US, EUROPE AND BEYOND This report provides an introduction focusing on the cardiac rhythm management (CRM) market and market leaders, Medtronic, Boston Scientific and St Jude Medical (SJM) and the difficult time they are facing in the CRM marke
Published Date: Sep 2013
Published By: Espicom

Price: $1740
Understanding Japans Regional Health Markets
A forensic analysis with statistics on national and regional health infrastructure and provision. An essential source of highly detailed business data. The popular view of the Japanese health market contains much myth and assumption. Despite long term economic woes and the impact of the tsunami in March 2011, Japan’s position as the world’s 2nd biggest market by health expenditure represents a technologically advanced country self sufficient in meeting the needs of its health system and population. But will that be true in the future? Any assessment of Japan must consider the impact of recent natural disasters, and the economic and demographic challenges that are influencing the development of the health market.  How is wealth distributed regionally?  Wh
Published Date: Sep 2013
Published By: Espicom

Price: $725
Opportunities in Advanced Wound Closure
The global market for wound closure products was worth approximately US$6.3 billion in 2012 and rose by 4% compared with 2011 levels. The principal drivers of growth are the rising numbers of surgical procedures being performed globally and the increasing adoption of advanced biosurgery products such as surgical sealants and haemostats by clinicians. There is a geographical twist, with higher demand in emerging economies for lower-cost traditional wound closure products, while newer technologies are finding more favourable conditions in western markets, principally the US. Despite these positives, the sector faces challenges. The weak global economy and health payer cost control policies have impacted healthcare spending. In such a market, healthcare providers are not always inclined
Published Date: Sep 2013
Published By: Espicom

Price: $760
The Worldwide Pharmaceutical Market Forecasts to 2018
This analysis report is an essential resource for business forecasters, marketing planners, the investment community and anyone looking to understand the future outlook for the dynamic pharmaceutical industry. With this report you have instant access to thousands of market projections and ranking to inform and direct your future operations. The report, compiled by Espicom’s pharmaceutical market experts with 30 years’ experience in the industry, provides you with global, regional and national views on the worldwide pharmaceutical market to reveal key insights into the future outlook: A global overview of key rankings Five regional sections allowing comparative assessment of countries within a geographic region: • Americas • Asia/Pacific • Central/E
Published Date: Aug 2013
Published By: Espicom

Price: $2995
The Worldwide Medical Market Forecasts 2018
This analysis report – The Worldwide Medical Market Forecasts to 2018 (published August 2013) – is an essential resource for business forecasters, marketing planners, the investment community and anyone looking to understand the future outlook for the dynamic medical device and equipment industry. With this report you have instant access to thousands of market projections and rankings to inform and direct your future operations. You benefit from: Growth forecasts to 2018 for 67 key country markets Comparative data on a regional and global basis Rankings by indicators allowing ‘at a glance’ benchmarking of countries Detailed information on each market PDF delivery with a complementary interactive data tool Easily exported data and graphs to enhance y
Published Date: Aug 2013
Published By: Espicom

Price: $2995
The World Pharmaceutical Markets Fact Book 2013
The indispensable source of thousands of facts, figures and statistics for 67 pharmaceutical markets worldwide! The World Pharmaceutical Market Fact Book 2013 is the ideal companion in today’s challenging pharmaceutical market environment. The need to understand world pharmaceutical marketplaces, and be able to answer quickly those questions that arise daily, is essential. That is why this current and comprehensive source of key market statistics is an invaluable aid for every pharmaceutical industry executive. Proven and reliable Published by Espicom - experts in the healthcare field for over 30 years, the Fact Book brings together a range of often difficult to source information in one single, convenient and comprehensive publication. Key market questions answered by
Published Date: Aug 2013
Published By: Espicom

Price: $1545
Biosimilar Opportunities in an Evolving Market
The long awaited promise of biosimilars takes another step to fulfilment with the first approval in Europe of high-value second generation products. But what products can be expected to follow, who is developing them and what are the hot prospects? Biosimilars: another milestone passed At the end of June 2013, the European Medicines Agency’s Committee for Medical Products for Human Use issued a positive opinion for the first biosimilar version of Johnson & Johnson’s infliximab for the treatment of rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis. For the two successful applicants, Celltrion and Hospira, this development passes a significant milestone for the whole biosimilar sector as the products are the first monoclonal antibody (mAb) therapie
Published Date: Aug 2013
Published By: Espicom

Price: $1495
Challenges and Opportunities-in the Renal Denervation Market
Hypertension: Prevalence and Significance Hypertension is one of the most preventable causes of premature morbidity and mortality globally. It is a major risk factor for stroke, myocardial infarction, heart failure, chronic kidney disease, peripheral vascular disease, cognitive decline, damage to retinal blood vessels and visual impairment, and premature death. Therefore, reducing hypertension can lower the incidence of these conditions, helping to improve the health of the population and reducing the high burdens that they place on global healthcare systems. Renal denervation therapy involves a surgical procedure and is therefore a last resort in the treatment of hypertension. It is only considered when cheaper, simpler and potentially safer alternatives such as lifestyle modifica
Published Date: Jul 2013
Published By: Espicom

Price: $1495
The World Medical Markets Fact Book 2013
The indispensable source of thousands of facts, figures and statistics for 67 medical markets worldwide! The World Medical Markets Fact Book 2013 is the ideal companion in today’s challenging medical market environment. The need to understand world medical marketplaces, and be able to answer quickly those questions that arise daily, is essential. That is why this current and comprehensive source of key market statistics is an invaluable aid for every medical device industry executive. Proven and reliable Published by Espicom - experts in the healthcare field for over 30 years, the Fact Book brings together a range of often difficult to source information in one single, convenient and comprehensive publication. Key market questions answered by The World Medical Markets Fac
Published Date: Jul 2013
Published By: Espicom

Price: $1545
The Silent Killer: Recent Advances in Cardiovascular Disease
There are nearly 300 medicines in clinical development to treat cardiovascular disease. This new research report examines in detail the key areas of the cardiovascular (CV) market, gathering inside opinion of cardiologists, to highlight the dynamic changes that are underway in this multibillion dollar marketplace. Successful players will, necessarily, need to cannibalise their existing cardiovascular franchises in order to limit the impact of generic erosion when their patents expire, whilst at the same time investing in alternative therapies with better, more efficacious outcomes. This is a significant challenge given the high barrier to entry and unmet clinical needs. Not only is cardiovascular disease a “Silent Killer”, it is also a commercial time bomb where the risk/r
Published Date: Jun 2013
Published By: Espicom

Price: $1495
World Generic Market Report 2013
A complete global analysis of the prospects for markets and companies in this dynamic industry sector Features and benefits of this thoroughly-researched and highly-regarded management report: High quality research and forecasts: Independent research, combined with detailed 5-year forecasts, informed commentary and unrivalled primary source data will aid your business planning and decision-making process Global coverage - with 74 country markets profiles: Scope opportunities for new investment or sales growth, with detailed historical data and forecasts on the leading developed economies as well as key emerging markets from Africa, the Americas, Asia, Emerging Europe, and the Middle East Issue driven: Understand the latest company, product, and regulatory developments Compan
Published Date: Jun 2013
Published By: Espicom

Price: $1595
Point of Care Diagnostics Market: Products, Players and Outlook
Vol 1: Cardiology Diagnostics | Vol 2: Hospital-based Diagnostics | Vol 3: Physician-based Diagnostics | Vol 4: Infectious Diseases Diagnostics A complete and practical analysis packed with facts, figures, forecasts and product/competitive assessments  Critical analysis and 5-year forecasts of key point-of-care diagnostic technologies, their prospects and the companies driving change and innovation. The In Vitro diagnostics market was worth approximately US$43 billion in 2011 and grew approximately 4% compared with 2010. The Point-of-Care (POC) sector represents 35% of the overall market and was valued at US$15.1 billion in 2011. The products covered in this report include those used by healthcare professionals and self-testers, which accounted for 33% of the POC sector,
Published Date: May 2013
Published By: Espicom

Price: $3615
The Medical Device Market: Peru
Peru is often overlooked when discussing the rapid-growth economies of South America. While it has neither the size nor the wealth of Brazil or Argentina, the country has recorded strong economic growth in recent years, except in 2009, when economic growth was very modest, reflecting global economic issues. Between 2012 and 2017, GDP is expected to rise every year, reaching a projected US$286.5 billion in 2017. Per capita wealth has risen, especially in and around Lima. This has led to the emergence of a sizeable urban population which demands improved healthcare, and increasingly has the ability to pay for it. Per capita GDP is projected to rise from US$6,530 in 2012 to US$8,838 in 2017. The Peruvian medical device market is one of the smallest in Latin America, and per capita consum
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Philippines
Despite having one of the largest populations in the world, let alone ASEAN, the country remains largely poor, and most of the opportunities are centred around Manila and surrounding areas on the island of Luzon, with areas such as Mindanao lagging behind overall. The Philippines medical device market is expected to grow at a solid 8.8% in the medium term. This growth will be spearheaded by the growth of imports, health expenditure, the private sector and medical tourism.  The Philippines has a history of political instability. The current ruling administration has had its fair share of controversy. The highly devolved health sector makes it difficult to stamp out corruption and other bureaucratic problems. Medical device spending is around US$3 per capita in 2012, simila
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Canada
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy.  The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. Canada is geographically one of the world’s largest countries, but has a populatio
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: China
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts.     China has the world’s largest population. In 2009, it was officially estimated a
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Cuba
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. Cuba’s imported medical device market grew rapidly up to 2007, however this was followed by
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Finland
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. Finland is one of the northernmost countries in Europe and covers around 338,000km2, of which 10%
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Ireland
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. With a population of around 4.1 million, the Republic of Ireland represents a small but advanced
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: UAE
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. The MoH has allocated over SR7 billion (approximately US$2 billion) for 67 health projects throug
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Latvia
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. Latvia is one of the smallest countries in Europe. It joined the EU in May 2004. In 2011, it has
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Lithuania
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. The Republic of Lithuania is situated in north-eastern Europe and is the largest of the three Bal
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Greece
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. Greece is one of the least affluent members of the European Union. GDP is US$269.5 billion in 201
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Venezuela
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. The volatile Venezuelan market for medical equipment & supplies is almost entirely supplied b
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: France
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. France ranks among the top five largest medical device markets in the world. Consumption of medical e
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Russia
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. The Russian market is potentially huge, given its population and potential wealth of natural resour
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Hong Kong
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy.  The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts.   Ruled by China since 1997, Hong Kong acts as a hub for trade throughout the regio
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Jordan
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts.   Jordan is a small but strategically located country in the Middle East, which borders Israel,
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Israel
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. Israel borders Lebanon, Syria, Jordan, Egypt and the Mediterranean Sea. Lying within its borders ar
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Serbia
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Australia
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. Australia is one of the richest healthcare markets in the Asia-Pacific region. The market ranks as th
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: South Africa
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date w
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Singapore
12Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date
Published Date: Apr 2013
Published By: Espicom

Price: $1295
The Medical Device Market: Slovenia
Espicom’s in-depth medical device market reports are ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date
Published Date: Apr 2013
Published By: Espicom

Price: $1295